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Abstract
Preterm birth is one of the most common causes of neonatal morbidity and
mortality. The incidence of preterm birth can be reduced by treatment with vaginal
progesterone or cervical pessary. However, no studies have supported a treatment
regimen that can reduce preterm birth in twin pregnancies. In this study, we will
examine whether a combination therapy of vaginal progesterone and cervical
pessary can reduce preterm birth in women with dichorionic-diamniotic twin
gestations. We will enroll pregnant women with dichorionic-diamniotic twins at 1114 weeks’ gestation from a local hospital in a randomized control trial. This novel
approach may help establish a new management option for twin pregnancies and
significantly decrease the morbidity and mortality that affects them.

v

CHAPTER 1: INTRODUCTION
1.1 Background
1.1.1 Preterm birth epidemiology in the United States
Preterm birth is defined as delivery prior to 37 completed weeks of gestation
and is one of the most common complications of pregnancy.1,2 In the United States,
preterm birth is the most common cause of neonatal morbidity and mortality
accounting for at least one-third of infant deaths and is the second most common cause
of death in children under 5 years of age.3,4 Preterm neonates that are born before 32
weeks of gestation are at a higher risk of complications, such as respiratory distress
syndrome (RDS), intra ventricular hemorrhage (IVH), and necrotizing enterocolitis
(NEC).4,5 Premature newborns may require prolonged hospitalization and lifelong
medical treatments.4,6 While various etiologies account for preterm delivery, one of
the major risk factors for preterm delivery is multiple gestations (i.e. twins and higher
order multiples).
The rate of twin births has risen 76% from 1980 to 2009, and the rate of
preterm delivery among multiple gestations has also increased during this time
period.8 Studies have shown that there is a causal effect between twin pregnancies and
preterm birth.7,8 Other studies have also discovered that the rate of preterm births due
to twin pregnancies has increased from 11.8% in 1995 to 16.7% in 2013.7 In the
United States, twins account for 10% of premature births and about 23% of all preterm
births that occur before 32 weeks of gestation.9 Twins can suffer from both
spontaneous and indicated preterm births, but more than 70% of preterm births in
multiple gestations are spontaneous.13 Increased incidence of twin gestations
combined with their increased preterm birth in twin gestations is one of the major
factors for the persistently high rates of preterm birth overall in the United States.7
1

Twins born prematurely have a 4 times higher risk of mortality when compared to a
singleton born at the same gestational age.10 Similarly, late preterm birth (gestational
age between 34 weeks 0 day and 36 weeks 6 days) has a minimal effect on increasing
mortality in singletons. However, late preterm births in twins lead to 3 times higher
risk of mortality.7 Overall, premature birth is responsible for greater than 50% of all
neonatal deaths for multiple gestations.11 Although a great deal of effort has been
placed into reducing the incidence of preterm births, the majority of these efforts are
being focused on singleton pregnancies.7-11 As a result, the effectiveness of
interventions to reduce preterm births in twin pregnancies is not well understood.7-10
Given that this is a high-risk population, a greater emphasis needs to be placed on
establishing effective interventions to reduce the rate of preterm births in twin
gestations.

1.1.2 Screening for Preterm Births
Accurately predicting preterm delivery has been challenging in patients
without a history of prior preterm delivery. Currently, transvaginal ultrasound (TVU)
is used to measure cervical length to stratify patients for risk of cervical insufficiency
and preterm delivery.12 Screening asymptomatic singleton pregnancies with TVU is
usually done between 16 and 23 weeks’ gestation.12,19 In singleton gestations, a
cervical length of less than 35mm is considered short, and if it is less than or equal to
20mm, vaginal progesterone treatment is indicated.12,19 Asymptomatic multiple
gestation TVU screening is not recommended in clinical practice, despite carrying a
higher risk than singleton gestations, because there are no effective treatment
modalities developed for multiple gestations yet.12 Even with screening, predicting
premature birth can be very difficult in multiple gestations as the association between
2

cervical length and risk of preterm labor is not as well understood in these cases.12,19
Since spontaneous preterm births are much more common than indicated preterm
births in twin pregnancies, observing and waiting for the cervical length to change
could delay proper treatment.

1.1.3 Current Treatment Options for Reducing Preterm Deliveries in Multiple
Gestations
Currently, limited treatment options are available to patients with multiple
gestations that are at a high risk of delivering prematurely. Studies have shown that
progesterone supplementation significantly decreases the rate of preterm birth in highrisk singleton pregnancies.7 During the past several decades, multiple studies have
attempted to discover effective treatments that could lower the incidence of premature
birth in twin pregnancies and delay birth to increase the gestational age.13-16 Treatment
modalities, such as intramuscular 17 alpha-hydroxyprogesterone or natural vaginal
progesterone, that were effective in preventing premature birth in singleton
pregnancies, did not show the same benefit in twin pregnancies.15,16 Additionally,
utilizing higher dose vaginal progesterone did not demonstrate any benefit.17 While
progesterone may not be effective at preventing preterm birth in twins, combining it
with a cervical pessary may produce a greater therapeutic response.13-16
Cervical pessary is a round silicone medical device placed at the opening of
the cervix in women at risk of preterm birth, usually between 16 weeks and 22 weeks
of gestation, has shown conflicting results.18,19,31 Studies have shown it can reduce
preterm birth before 34 weeks of gestation in singleton pregnancies with a short
cervical length/cervical insufficiency.19,20 However, there are no changes in neonatal
morbidity or mortality between the two singleton groups.19-21 Subsequent studies
3

could not duplicate these results and found no difference.19-21 Studies that specifically
utilized cervical pessary in unselected twin pregnancies found no overall treatment
benefit in the pessary group, but the results showed that it significantly decreased
premature birth rates before 32 weeks’ gestation in a certain population of women
with cervical insufficiency who had a cervical length was less than the 25th percentile
(< 38mm).19,24, Furthermore, the rate of composite perinatal outcomes was
significantly lower in this subgroup of women compared to the placebo group.22-24
Although the effects progesterone and cervical pessary have shown conflicting
results across studies, it does reveal that they might have a potential as a treatment
modality, especially for women with twin gestations and cervical insufficiency.19,25,26
Because cervical shortening can be detrimental to twin pregnancies, resulting in
preterm birth and severe neonatal morbidity and mortality, it might be beneficial to
utilize a cervical pessary with progesterone since it has not been shown to cause any
negative side effects.18,19,24-26 Generally, a cervical pessary is inserted around 16 to 22
weeks’ gestation for both singleton and twin pregnancies.19 This new intervention
might potentially improve outcomes by implementing it alongside daily vaginal
progesterone between 11 to 14 weeks, which will be continued until the twins are
delivered or until 38 weeks’ gestation.19

1.1.4 The Role of Supplemental Progesterone on Reducing Preterm Birth Risk
Progesterone is a steroid hormone that has essential roles throughout
pregnancy and is involved during the delivery process.16,27 It is imperative in the
process of uterine contractions, sustains decidualization, and has a role in promoting
the immunity of the mother against fetal semi-allografts.27 A number of studies have
observed an increasing level of progesterone from conception to delivery.17,28,29
4

Progesterone hormone receptors are found throughout the uterus and cervix and
regulate the effects of progesterone in pregnancy.27 Progesterone’s effects on the
myometrium in the uterus allows for remodeling to facilitate the growth of the
fetus.27,28 Progesterone produced by the placenta, ovaries, and adrenal glands maintain
uterine quiescence to prevent the onset of labor.16,27,28It inhibits the propagation of
uterine contractions by preventing the synthesis of cell gap junctions in the
myometrium.27 Additionally, it acts to inhibit oxytocin and prostaglandin signals that
are involved in the initiation of the parturition process.27 The integrity of the cervix,
which further facilitates gestation, is maintained through the actions of progesterone
which prevents the breakdown of collagen in the cervical stroma.27
Low serum levels of progesterone have been correlated with an increased risk
of preterm birth and threatened miscarriage.19,27,29 Generally, when a woman has
reached full term of gestation, a reduction in progesterone levels or modulation of
progesterone receptors results in the onset of labor.29 This is associated with an
increase in uterine contractility, which is subsequently followed by the delivery of the
fetus.29 Thus, women that have a suboptimal level of progesterone production are at
risk of early delivery.19,29 As a primary preventative measure, there has been a
particular focus on the role of supplemental progesterone on reducing the risk of
preterm delivery. The route of administration has been shown to have immense effects
on the efficacy and safety of its use in the prevention of preterm delivery.19,27,29 It is
been advised that oral progesterone should be avoided given that first-pass hepatic
metabolism reduces its bioavailability, while simultaneously exposing the mother to
an increased risk of side-effects.16,27 Vaginal administration of progesterone bypasses
first-pass hepatic metabolism and has local endometrial effects, is rapidly absorbed,
has minimal systemic side effects, and a high bioavailability.16 As a result, vaginal
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administration is considered to be safe in pregnancy and has been approved by the
United States Food and Drug Administration (FDA) in 2011.16 A number of studies
have shown that progesterone supplementation in pregnancy can have the same effects
as endogenous progesterone and consequently facilitate fetal growth, maintain
gestations, and prevent early onset labor by impeding uterine contractility, thus
reducing the risk of preterm deliveries and consequent neonatal morbidity and
mortality.16,17,27-29 Although progesterone supplementation in pregnancy has been
proven to have significant positive outcomes in singleton pregnancies, the effect of
this intervention on multiple pregnancies is still not well understood.16,17,27-29

1.1.5 The Future of Interventions for Treatment of Preterm Births in Multiple
Gestations
Novel and effective treatments are urgently needed to decrease the incidence
of preterm birth, and subsequent neonatal morbidity and mortality, in twin gestations.
A prospective open-label randomized controlled clinical trial is proposed to
investigate the utility of late first trimester combined vaginal progesterone and
cervical pessary use to prevent preterm delivery in unselected dichorionic-diamniotic
(DCDA) twin gestations. This intervention differs from previous studies on twin
preterm birth treatments because it implements cervical pessary alongside
progesterone rather than investigating their use as monotherapies. Because this study
consists of unselected twin gestations, cervical length would not be used for inclusion
or exclusion study criteria. Using unselected twins allows for the intervention to start
between 11 to 14 weeks’ gestation rather than 16 to 22 weeks, in contrast to other
studies.19 Starting the intervention between 11 to 14 weeks’ gestation could allow for a
prophylactic treatment, which might increase the average gestational age in twin
6

pregnancies. Since a short cervical length is a major risk factor for premature birth,
starting treatment earlier might prevent or delay the initial shortening process. Using a
new method of implementing treatment sooner in the pregnancy might prove to
increase gestational age.
With multiple studies being unable to find a solution to delaying preterm birth
in twins, unexplored novel ideas must be tested to discover an effective treatment
intervention for this ongoing issue. Intervention involving both vaginal progesterone
and cervical pessary can easily be introduced earlier in pregnancy and used in clinical
practice if proven to be effective, because they are non-invasive, affordable, have no
known adverse effects, and could potentially lead to a decrease in the overall cost of
care.19,25

1.2 Problem Statement
Even with the significant increase in risk, incidence, morbidity and mortality,
there are no effective treatment options for preventing preterm birth in twin
gestations.5,6 Previous clinical trials that studied the effectiveness of interventions to
prevent preterm birth in singleton gestations have been unable to provide statistically
significant results for twin pregnancies.5 Novel studies must be done to explore new
ways to effectively use these interventions to treat premature birth in twin gestations,
or definitively determine they do not work, prompting investigation into completely
different treatments. In either case, further research is needed to improve the severe
morbidity and mortality associated with preterm birth and twin pregnancies.

7

1.3 Goals and Objectives
The goal of this study is to investigate the effectiveness of combined vaginal
progesterone supplementation and cervical pessary initiated in the late first trimester
in prolongation of gestation and prevention of preterm delivery in unselected DCDA
twin gestations. The primary objective of this study is to compare the effect of
combined vaginal progesterone supplementation and cervical pessary (starting
between 11 to 14 weeks’ gestation until 37 weeks’ gestation or birth) vs. no
intervention in women pregnant with twins on the rate of preterm birth in DCDA twin
gestations. Studies designed to decrease preterm birth has been done before and is an
easy to track dichotomous outcome.
The secondary objective of this study is to investigate the effect of this
intervention on a composite outcome of overall gestational age; level of preterm birth
grouped by certain gestational ages (before 35, 34, 32 and 28 weeks of gestation);
cervical length changes throughout pregnancy; birth weight; and neonatal morbidity
and mortality in pregnancies treated with combined vaginal progesterone
supplementation and concomitant cervical pessary initiated in the late first trimester in
unselected DCDA twin gestations. Neonatal morbidity and mortality will be assessed
by determining and comparing the APGAR score; admission to and time spent in the
neonatal intensive care unit (NICU); and composite neonatal outcomes (the
occurrence of any of the following events: RDS, IVH, sepsis, NEC, and death before
hospital discharge) in the intervention group and the control group.
Comparing overall gestational age adds novelty to the study and sets it up for
success. Because preterm birth is extremely common and difficult to treat in twin
gestations, it is essential to conduct a study that can also establish a statistically
significant treatment to lengthen average gestational age. Discovering statistically
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significant improvements in these outcomes could also establish this intervention as
the treatment of choice for preventing morbidity and mortality in premature twin
gestations.

1.4 Research Questions
1. In twin gestations, without a maternal history of preterm birth, can the early (1114 weeks’ gestation) administration of both a daily vaginal progesterone and
cervical pessary cause a reduction in preterm delivery rates compared to
controls that undergo standard antenatal care?
2. In twin gestations, without a maternal history of preterm birth, can the early (1114 weeks’ gestation) administration of both daily vaginal progesterone and
cervical pessary decrease composite neonatal morbidity and mortality compared
to controls, who will receive the standard of care?

1.5 Hypothesis
It is hypothesized that the combined use of vaginal progesterone and cervical
pessary from 11 to 14 weeks’ gestation (until 37 weeks’ gestation) will result in a
20% decrease in the rate of preterm births in DCDA twin gestations compared to
women that receive standard cares during the same timeframe.

1.6 Definitions
1. Vaginal progesterone: Vaginal progesterone is a form of medical intervention
that involves vaginally administering a tablet formulation containing either a
natural or synthetic form of the endogenous steroid hormone progesterone.30
Upon insertion, the progesterone binds to the progesterone receptor, which
9

results in receptor phosphorylation, the dissociation of heat shock proteins, and
transcription activation.30 The activation of the progesterone receptor results in
an increase in estrogen metabolism and a reduction in the number of viable
estrogen receptors.27,29,30 Progesterone results in a decrease in uterine
contractility in pregnancy, secretory endometrial changes, and results in the
maintenance of pregnancy.27,30
2. Cervical pessary: A cervical pessary is a round silicone medical device that is
placed at the opening of the cervix. This medical device is placed early in
pregnancy in women that are at risk of preterm birth and is removed later when
this risk has elapsed.31
3. Gestation: The time period between conception and birth.32
4. Preterm: The birth of an alive neonate prior to completion of 37 weeks of
gestation. Subcategories include moderate to late preterm (32 to 37 weeks),
very preterm (28 to 32 weeks), and extremely preterm (less than 28 weeks).33
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CHAPTER 2: REVIEW OF LITERATURE
2.1 Introduction
The purpose of this literature review was to analyze the available evidence that
is currently available in preterm birth management in twin gestations. Additionally, it
aimed to identify which medical intervention was most effective at preventing preterm
birth in twin pregnancies (vaginal progesterone administration vs. cervical pessary
plus expectant management).

2.1.1 Excisional Sources
An a-priori designed protocol model was used to perform this review. An
electronic search of PubMed, Scopus, Ovid, MEDLINE and Cochrane was conducted
from July 2020 to July 2021 utilizing a combination of relevant keywords, medical
subject heading terms, and word variants for “preterm birth” and “twin pregnancies”.
The full list of keywords used in different combinations is outlined in table 1. Another
hand search was performed in relevant articles to determine if their reference lists
contained any additional relevant reports. The PRISMA guidelines were followed.

Table 1: The full list of keywords used to search databases for relevant literature
Keywords Used
Twin gestation
Multiple pregnancies
Multiple fetuses
Preterm birth
Gestational age
Cervical pessary
Vaginal progesterone
Tocolytic therapy
Cesarean section
Vaginal infections
Vaginal discharge
Steroid administration
13

Intra-uterine death
Neonatal death
Perinatal death
APGAR score
Birthweight
RDS
IVH

NEC
Sepsis
Retinopathy of prematurity
Bronchopulmonary dysplasia
Mechanical ventilation
NICU

2.1.2 Eligibility Criteria and Main Outcome Measures
The inclusion criteria for studies included randomized control trials in which
twin gestations were randomized to either a control group (standard treatments or a
placebo) or an intervention group receiving treatment for the prevention of preterm
birth (any type of cervical cerclage, progesterone, cervical pessary, or a combination
of these). The primary outcomes included preterm birth that was < 34 weeks of
gestation. Secondary outcomes included: Preterm birth < 24 weeks; preterm birth < 28
weeks; preterm birth < 32 weeks; preterm birth < 37 weeks; gestational age at delivery
(in weeks, continuous variable); intra-uterine death (either twin after 22 weeks of
gestation); neonatal death (either twin up to 28 days of life); perinatal death (the sum
of intra-uterine deaths and neonatal deaths); APGAR score <7 (calculated at 5
minutes); birthweight < 2500 g; RDS; NEC; sepsis; the need for mechanical
ventilation; admission to the NICU. The primary and secondary outcomes were
investigated in an unselected cohort of twin gestations.
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2.1.3 Data Collection and Analysis
Relevant studies were extracted and reviewed by an independent third party to
ensure the reliability and quality of included research. The risk of bias in the included
studies was assessed through the Revised Cochrane risk-of-bias tool for randomized
control trials. Each study was assessed for risk of bias arising from five domains:
missing data, randomization procedures, protocol deviations, measurement, and
reporting of results. The risk of bias was considered low if at least four of the domains
were rated as being low risk, with at least one of these domains being random
allocation to groups and allocation concealment. The strength of the recommendations
and quality of the included evidence was assessed through the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) method.4

2.1.4 Results
Overall, 78 articles were identified, 64 were not included because they did not
meet eligibility, 14 did. I especially focused on these 3 studies for the literature review
after been deemed relevant to the current study (outlined in table 2). Other articles
were also reviewed to look at confounders that might affect this proposed study.

Table 2: General characteristics of the included studies
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Author

Year

Country

Period
Considered
2010 to 2014

Merced et
al.1

2019

Spain

Rehal et
al.2

2021

England,
2017 to 2019
Spain,
Italy,
Bulgaria,
France, and
Belgium

Shabaan
et al.3

2018

Egypt

2015 to 2017

Inclusion Criteria

Intervention

Twin pregnancies,
minimum maternal age
18 years, arrested
preterm labor, cervical
insufficiency, and
gestational age between
24 and 33 weeks
Maternal age older than
18 years, 2 live fetuses
at the 11 to 13 weeks’
scan, dichorionic or
monochorionic
diamniotic twin
pregnancies, fluency in
the local language
Naturally conceived,
uncomplicated
pregnancy, dichorionic
diamniotic twin
gestation, no major fetal
abnormalities

Cervical pessary
placement

Description of
intervention
65mm x 25 mm x 35
mm cervical pessary

Vaginal
progesterone

300mg bid from 11 to
14 until 34 weeks’
gestation

Vaginal
progesterone

400mg administered
once daily
(“bedtime”) through
vaginal pessary

2.2 Effect of Vaginal Progesterone Administration and Cervical Pessary Insertion on
Singleton Pregnancies
A review of the effect of vaginal progesterone administration and cervical
pessary insertion on singleton pregnancies was conducted to determine the rate of
reduction of preterm births that could be expected from using the same intervention in
twin gestations. A cohort study conducted by Stricker et al. (2016) in 53 pregnant
women with singleton gestations found that treatment with combined cervical pessary
and progesterone did not result in a reduction in preterm deliveries compared to
cervical pessary alone.23 Delivery prior to 34 weeks of gestation occurred in 32.1% of
participants that were given the combined intervention compared to 24.5% of
participants that received monotherapy with cervical pessary.23 However, it was found
that there was a reduction in admission to the NICU in women that received combined
treatment compared to monotherapy.23 In contrast, a retrospective evaluation
conducted by Tajima et al. (2020) on 95 pregnant women with singleton gestations
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found that there was a 22.2% reduction in the rate of preterm deliveries in women that
received combined vaginal progesterone and cervical pessary compared to women that
received tocolysis (7.0% compared to 30.8% rate of deliveries before 36 weeks of
gestation).24 Similarly, Daskalakis et al. (2018) discovered through a prospective
cohort study that combined vaginal progesterone and cervical pessary reduced the rate
of preterm births in singleton pregnancies by 11.9% when compared to no intervention
(44.4% vs. 32.5%).25 Thus, it can be expected that if similar results are observed in the
current study, combined vaginal progesterone and cervical pessary should have an
estimated effect in reducing preterm birth rates in twin gestations by 10 to 20%.

2.3 Review of Empirical Literature on the Effect of Cervical Pessary Insertion on
Preterm Birth Rates in Twin Gestations
To date, there has been no intervention that has been proven to be effective in
reducing preterm birth rates in twin gestation, particularly in cases of known risk
factors including a cervical insufficiency and threatened preterm labor. Merced et al.
(2019) conducted an open, randomized, controlled trial to determine if cervical
pessaries were beneficial in preventing birth before 34 weeks of gestation in women
with twin pregnancies with the aforementioned risk factors.1 Their results revealed
that the use of cervical pessary vs. no intervention resulted in a significant reduction in
birth rates before 34 weeks of gestation (16.4% vs. 32.3%).1
Similar findings were also seen in a few other studies. A retrospective cohort
identified women with cervical insufficiency (cervical length < 20 mm) and assessed the
association of cervical pessary inserted before 28 weeks of gestation in twin pregnancies
compared to no intervention.7 Findings were suggestive of lower incidence of delivery at
< 32 weeks (p=0.05), prolonged interval to delivery (p=0.025), and reduced incidence of
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severe neonatal morbidity (p=0.04).7 Others studies showed that cervical pessary
reduced preterm birth before 34 weeks’ gestation in singleton pregnancies with a short
cervical length.5,8 However, neonatal morbidity did not differ between the two
groups.5,8,9
Studies that specifically utilized cervical pessary in unselected twin pregnancies
found no overall treatment effect in the pessary group, but the results showed that it
significantly decreased premature birth rates before 32 weeks’ gestation in a certain
population of women whose cervical length was less than the 25th percentile (<
38mm).5,10 Furthermore, the rate of composite perinatal outcomes was significantly
lower in this subgroup of women compared to the placebo group.10-12

2.4 Review of Empirical Literature on the Effect of Vaginal Progesterone
Administration on Preterm Birth Rates in Twin Gestations
Intramuscular/vaginal has been shown to be effective in reducing the rate of
preterm birth in singleton pregnancies, with no additional benefit at higher doses.13-16
A meta-analysis conducted in 1990 collated evidence from 7 controlled trials for the
outcomes of progesterone agents during pregnancy.17 Only women who were at high
risk of preterm birth were selected and the outcomes also included neonatal morbidity
and mortality. Overall, there was no statistical effect of progesterone agents during
pregnancy with neonatal morbidity and mortality. However, intramuscular 17 alphahydroxyprogesterone caproates did decrease the overall incidence of preterm birth.17
There has been a renewed interest in the outcomes of vaginal progesterone for recurrent
or at-risk mothers for preterm birth. Two clinical trials demonstrated a reduction in
preterm birth with both natural vaginal progesterone and synthetic progesterone
administered intramuscularly.18,19 However, considerations for the impact of prolonging
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gestation on neonatal morbidities including respiratory distress are also of interest.
Another clinical trial randomized women between 18-23 weeks with either live singleton
or twin pregnancy with a previous history of preterm birth to administer vaginal
progesterone. There were no major differences in the incidence of respiratory distress
syndrome (10.5% in the intervention group vs. 10.6% in the placebo group) (95% CI
0.69-1.53, p=0.905).20 There were also no differences in the rate of maternal morbidities
associated with side effects (9.9% in the intervention group vs. 7.3% in the placebo
group) (95% CI 0.85-2.15, p=0.204).20 Overall, data has not been conflicting regarding
neonatal outcomes yet there is improved gestational age when vaginal progesterone is
administered at 18-23 weeks.19,20
Rehal et al. (2021) aimed to determine if the positive effects of vaginal
progesterone could be extrapolated to multiple gestations. They conducted a
randomized, placebo-controlled, double-blind trial to determine if the administration
of daily vaginal progesterone 600mg from 11 to 14 weeks until 34 weeks’ gestation in
twin pregnancies influenced the rates of spontaneous preterm births. They observed a
spontaneous births between 24 to 34 weeks of gestation among the intervention group
of 10.4% in the progesterone group compared to 8.2% in the placebo group (95% CI
0.88-2.05, p=0.17).2 However, they were able to find a minor benefit in preventing
preterm birth prior to 32 weeks’ gestation in those with a cervical length of < 30mm
(p=0.08).2 This indicates that progesterone may be beneficial in preventing preterm
birth between 24 to 32 weeks of gestation, however, this beneficial effect might not
extend to the third trimester of pregnancy.
Shabaan et al. (2018) performed a randomized, open-label, controlled trial on
70 pregnant women with twin pregnancies to determine the effect of vaginal
progesterone administration on the rates of preterm delivery. They compared these
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rates to women receiving no additional treatment beyond standard care. Unlike
Merced et al. (2019), Shabaan et al. (2018) did not observe a statistically significant
difference between preterm birth rates (delivery < 37 weeks) in women receiving
vaginal progesterone and the control group (16.9% vs. 25.4%, p=0.06).1,3
Furthermore, Shabaan et al. (2018) found that the mean gestational age between the
two groups was similar.3

2.5 Effect of Vaginal Progesterone and/or Cervical Pessary on Preterm Birth Rates in
Twin Gestation
A randomized controlled trial compared the efficacy of cervical pessaries with
vaginal progesterone for twin pregnancies at 16-22 weeks among women who had a
cervical length < 38 mm.21 They observed a 16% (n=24) preterm birth rate < 34 weeks’
gestation in the cervical pessary group compared to 22% (n=33) in the progesterone
group.21 Those with cervical insufficiency who had a cervical length of < 29 mm,
pessary reduced the birth rate before 34 weeks from 46% (n=16) to 21% (n=10) with
improvement in perinatal outcomes.21 Although progesterone and cervical pessary have
shown conflicting results, these studies reveal that they also show promising ones,
especially for women with twin gestations and cervical insufficiency.5,22
The combined use of vaginal progesterone and cervical pessary has also been
observed in twin pregnancies to determine the outcome of preterm births at 18-27
weeks of gestation.26 Among women with cervical insufficiency (cervical length of <
26 mm), there were no statistical differences between intervention and standard of
care groups for preterm birth < 34 weeks (40.0% in the intervention group vs. 18.8%
in the standard of care group, p=0.07).26 In terms of the birthweight, there were also
no statistical differences between intervention and standard of care groups.26
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However, an important predictor of preterm birth (< 34 weeks) in ongoing pregnancy
for women receiving both vaginal progesterone and cervical pessary in mothers with
twin pregnancies was the previous history of preterm birth (< 37 weeks) (p=0.031).26
A recent meta-analysis reviewed the outcomes of vaginal progesterone, cervical
pessary and cervical cerclage among women with twin pregnancies and short cervical
length (< 26 mm) with no risk in reduction of preterm birth < 34 weeks.27

2.6 Review of Empirical Literature on the Effect of Vaginal Progesterone and/or
Cervical Pessary on the Rates of Neonatal Morbidity and Mortality
In addition to reducing preterm birth, an important factor to measure is whether
the intervention decreases neonatal morbidity and mortality. Although Merced et al.
(2019) observed a significant reduction in the rates of spontaneous preterm births in
pregnant women that received a cervical pessary, they did not observe a significant
reduction in composite neonatal mortality..1 However, they did note statistically
significant reductions in neonatal birth weight less than 2500g, neonatal sepsis, and
NEC in the group that received cervical pessaries.1 Conversely, Rehal et al. (2021)
noted that the administration of vaginal progesterone did have a significant reduction
in the rate of neonatal mortality.2 They also noted that this intervention had a
significant reduction in neonatal respiratory distress syndrome, birth weight less than
1500g, and the need for mechanical ventilation.2 Unlike Rehal et al. (2020) and
Merced et al. (2019), Shabaan et al. (2019) observed no difference in neonatal
mortality and morbidity in women that received vaginal progesterone during
pregnancy and the control group receiving no additional treatment.3
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2.7 Review of Studies to Identify Potential Risk Factors/Confounders
There are many potential confounders for preterm birth such as baseline
genotypes, biochemical variables, lifestyle characteristics, socioeconomic status,
education level, etc., that have not been included in many previous studies and are
beyond the scope of this study. It is important to consider the potential for these
variables to act as confounding factors when evaluating the outcomes of the discussed
studies and when analyzing the results of the proposed study. However, there are
many risk factors that should be measured and adjusted for in the proposed study.

2.7.1 History of Preterm Birth
The most important risk factor that predicts preterm birth is a prior history of
preterm birth.45 The risk increases further if there was a history of more than one
preterm birth.45 If the gestational age was smaller, it further increases the risk of
preterm birth.45 For a twin gestation among mothers who have had a preterm singleton
gestation, the chance of recurrence is 57% (95% CI: 51.9-61.9).46 As twin pregnancy
itself is a risk factor for preterm birth, when compounded with a prior history of
preterm birth, it has a significant impact on the rate and severity of preterm birth.45,46

2.7.2 Maternal Risk Factors
There are notable ethnic disparities to consider with preterm birth. A metaanalysis conducted by Schaaf et al. (2012) highlighted the risk of preterm birth as
higher among non-white women (odds ratio=2.0, CI:1.8-2.2) when compared to
Caucasian mothers.28 However, findings demonstrated that while the rates of preterm
birth were higher among non-white women, the neonatal outcomes were better among
African American mothers.28 Maternal body mass index (BMI) is also another
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important risk factor for preterm birth. Women who are extremely underweight with a
BMI of < 17 kg/m2 have a higher risk of preterm birth (odds ratio=2.4, CI: 1.4-4.2).29
Potential reasons include macro-and micronutrient deficiencies that impair detail
growth. Also, women who are obese with a BMI >34.9 kg/m2 are also at increased
risk of developing premature rupture of membranes (odds ratio=1.6, CI: 1.1-2.3).29 In
these women, the circulating inflammatory agents are suspected to increase the rate of
preterm birth.29
Mothers who are actively smoking are also known to contribute to an
increased risk of preterm births.30 There have been many studies that have reported
the risk of smoking during pregnancy with very high rates of preterm births among
women. A meta-analysis demonstrated that the rate of preterm births significantly
reduced following a reduction in mothers who were smoking.31,32

2.7.3 Excisional Cervical Procedures
Preterm birth is frequently observed among women with a short cervix.33 The
use of cervical cerclage has been present since the 1950s for women with cervical
insufficiency.34 Overall, the outcomes of prophylactic cerclage have remained
unclear.34 A study reviewed the outcomes of cerclage among women who had
undergone conization.35 While there was no significant contribution relating to age or
years from conization, conization followed by cervical cerclage increased the risk of
preterm birth.35 Potential contributors include inflammation following cervical
cerclage and ensuing intra-amniotic inflammation resulting in elevated preterm birth
rates.35 The risk of developing spontaneous preterm birth < 35 weeks among women
who have had a history of the excisional procedure is 13%.35 A meta-analysis
conducted by Conner et al. (2014) identified the association between loop
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electrosurgical excision and preterm birth.36 Overall, there was a higher risk of
presenting with preterm birth < 37 weeks following loop electrosurgical excision
procedure (LEEP) (pooled relative risk= 1.60, 95% CI: 0.99-2.55), but these findings
were not statistically significant.36 Another meta-analysis conducted by Danhof et al.
(2015) compared the risk of preterm birth among women who had an excisional
procedure for cervical intraepithelial neoplasia prior to and while pregnant, to women
with cervical intraepithelial neoplasia that remained untreated.37 The outcomes
suggested that women who were treated during pregnancy had the highest risk of
preterm birth (OR=6.5, 95% CI: 1.1-3.7).37
A study conducted by Goldenberg et al. identified that a cervical length < 25
mm at 24 weeks was a strong predictor of preterm birth in twin pregnancies (odds
ratio= 6.9, 95% CI: 2.0-24.2).38 A meta-analysis presented interesting findings
concerning cervical length and early preterm birth for twin pregnancies. A cervical
length < 26 mm was shown to have a positive likelihood ratio of 9.6 (95% CI: 5.814.8) when screened at 20 weeks.39 While there is are no guidelines for the benefits of
screening for cervical length or cervical insufficiency, many preventive strategies are
being considered for twin pregnancies.39

2.7.4 Uterine Anomalies
Various uterine abnormalities such as the uterine didelphys, unicornuate uterus
uterine septum, and bicornate uterus contribute to preterm birth.40 A retrospective
study identified 203 women with singleton pregnancies who had a uterine anomaly.
The odds of having a preterm birth increased by 5.9 (95% CI: 4.3-8.1).40 Another
systematic review identified that the rate of preterm births increased among women
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with septate uteri (risk ratio=2.14, 95% CI: 1.48-3.11) and unification defects (risk
ratio=2.97, 95% CI: 2.08-4.23).41

2.7.5 Curettage History
Women who have had a history of pregnancy loss either due to termination
(abortion) or miscarriage and have been managed with cervical dilation and curettage
are known to be at higher risk of developing spontaneous preterm birth (odds
ratio=1.66, 95% CI: 1.14-2.42).42 The risk rises with a higher number of curettage
procedures.43 A meta-analysis conducted by Saccone et al. (2016) identified that a
spontaneous abortion (odds ratio=1.19, 95% CI: 1.03-1.37) and termination of
pregnancy (odds ratio=1.52, 95% CI: 1.08-2.16) were both independent predictors of
spontaneous preterm birth.44

2.7.6 Bacterial Vaginosis
Bacterial vaginosis is due to an overgrowth of certain bacteria in place of
normal vaginal lactobacilli. A meta-analysis conducted by Leitich et al. among 30,518
indicated that bacterial vaginosis doubled the risk for preterm birth (odds ratio=2.16,
95% CI: 1.56-3.00).47 However, the impact of bacterial vaginosis on twin pregnancy
remains unclear. Another meta-analysis demonstrated a weak association of bacterial
vaginosis in twin pregnancies.38 A Cochrane review identified no impact on preterm
birth rates among singleton pregnancies, high- and low-risk.48 However, another
Cochrane review concluded that treatment of bacterial vaginosis reduced the preterm
birth rate among high-risk singleton pregnancies (relative risk= 0.64, 95% CI: 0.470.88).49 The treatment with clindamycin before 22 weeks of gestation to mothers with
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bacterial vaginosis have shown efficacy for preterm birth < 37 weeks (relative risk=
0.60, 95% CI: 0.42-0.86).49

2.7.7 Group B Streptococcus Maternal Colonization
A meta-analysis conducted by Bianchi-Jassir et al. (2017) estimated the risk
ratio for preterm birth associated with maternal Group B streptococcus (GBS)
colonization to be significant.50 GBS colonization in mothers has been shown to
increase the risk of preterm birth (odds ratio=1.98, p<0.001, 95% CI: 1.45-2.69).50
Bacteriuria as an ascending infection is known to increase the risk of preterm birth
associated with maternal GBS.50 A retrospective cohort identified the burden of GBS
at 14 weeks of gestation in singleton pregnancies. The incidence of preterm birth was
significantly higher among the GBS-positive mothers (p=0.001).51

2.7.8 Fetal Anomalies
The risk of preterm birth for pregnancies associated with congenital fetal
anomalies varies upon the type of anomaly.52 Overall, the gastrointestinal anomaly
was associated with a 2.62-fold increase in the odds of developing a spontaneous
preterm birth (95% CI: 1.52-4.53).52 After adjusting for maternal age, ethnicity,
tobacco and substance use, and BMI, the risk of preterm birth increases by 4.81 fold
(95% CI: 2.86-8.09) with gastrointestinal anomaly and 3.66 fold (95% CI: 1.06-12.64)
for neck mass anomaly.52

2.7.9 Compliance with Vaginal Progesterone
Compliance is assessed by the patients returning medication packs, diaries,
and self-reports. It is calculated as the total number of doses taken divided by the
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expected doses. A study observed adequate compliance to be 80% or more among
women taking vaginal progesterone.53 Overall, over 82% (n=1011) of the women had
a compliance of over 80% in the trial.50 Two other studies reported a high compliance
rate of 93-96% among women for gel forms of vaginal progesterone.33,54 Another
form of vaginal progesterone including oil-in-capsule was less easy to use and
associated with higher vaginal discharge.55 However, the overall satisfaction of
vaginal progesterone is higher than that of intramuscular progesterone.56

2.7.10 Gestational Diabetes
For twin pregnancies, the risk of adverse outcomes with gestational diabetes
mellitus (GDM) is known to increase.57-59 A retrospective cohort study identified the
outcomes of twin pregnancies among mothers with GDM. There was a higher risk of
poor perinatal outcomes except for macrosomia.57 The risk of preterm birth was
increased by an OR of 58.82 (95% CI: 31.25-135, p<0.0001) among GDM mothers
expecting twins.57 Another study reported a lack of clear guidelines to manage
patients with twin GDM pregnancies.58 Overall, twin GDM pregnancies had a higher
risk of prematurity and perinatal mortality.58 There was also a higher rate of perinatal
mortality among twin GDM pregnancies compared to singleton pregnancies
(p=0.001).58 There are poorer outcomes of GDM with twins vs. singleton GDM
pregnancies.59 These women are known to be in a high-risk group with a lack of
clarity on dietary requirements, the timing of delivery, and glucose targets.59

2.8 Review of Empirical Literature on the Relevant Methodology of Studies
Merced et al. (2019) conducted an open, randomized, controlled trial in 132
pregnant women that had a short cervix (< 20 mm between 24 and 29 weeks of
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gestation and < 10 mm between 30 and 33 weeks of gestation) and did not deliver 48
hours after an episode of threatened preterm labor. This trial was conducted between
December 2010 and December 2014 in Barcelona, Spain, with ethics approval from
the hospital ethics committee. Inclusion criteria for the study included a minimum
maternal age of 18 years, twin pregnancies, and gestational age between 24 and 33
weeks with a short cervical length and arrested preterm labor. Exclusion criteria
included women with a cervical cerclage in situ, history of a cone biopsy, active
vaginal bleeding or ruptured membranes, and women with regular uterine contractions
despite tocolytic agent administration. The participants (n=132) were then randomized
into a pessary group (n=67) and control group (n=65). The pessary group had the
insertion of a cervical pessary, while the control group received routine management.
The participants were followed up on a monthly basis, with no women lost to follow
up. The methodology utilized by Merced et al. (2019) had a clear aim with an
appropriate and justified approach. The methodology was presented with a high
quality of detail to ensure that replication was possible. It was noted that Merced et al.
(2019) placed the cervical pessary in participants after 24 weeks of gestation. Hence, it
is not known whether earlier placement of the cervical pessary would have resulted in
a greater effect on the reduction in the rate of preterm deliveries.
The methodology employed by Rehal et al. (2021) was similar to that of
Merced et al. (2019) but on a larger scale. They recruited pregnant women with twin
gestations from 22 hospitals across Europe (n=1194). Inclusion criteria for recruitment
included pregnant women that were 18 years or older, 2 lives fetuses at 11 to 13
weeks’ scan, monochorionic diamniotic twin pregnancy, and fluency in the local
language. The eligible participants were assigned 1:1 to an intervention group and a
control group with a simple computer-generated block. The intervention group
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received a progesterone capsule to be vaginally administered while the control group
received a placebo capsule to be vaginally administered that was the same size and
shape as the progesterone pill. The intervention was commenced between 11 to 13
weeks of gestation. The method differed from Merced et al. (2019) at this point, as the
inclusion of a placebo allowed for double-blinding in the study. All the participants,
investigators, pharmacists, etc. were blinded to the allocation of the participants until
the end of the study. All participants were asked to administer one vaginal capsule
300mg twice daily until 34 weeks’ gestation or in the event of an unexpected early
delivery. All participants were followed up once every two weeks. The methodology
outlined by Rehal et al. (2021) was very detailed to allow for future reproduction. No
concerns were noted on the analysis of the method outlined by Rehal et al. (2021).
Shabaan et al. (2018) conducted an open-label, randomized, controlled trial
across three tertiary care centers in Egypt between 2015 and 2017. The inclusion
criteria included pregnant women at 28 weeks of gestation that were naturally
conceived, no known major fetal abnormalities, dichorionic diamniotic twins, and
uncomplicated pregnancy. In total, 158 women were recruited to participate in the
study, of which 18 were excluded due to not meeting the eligibility criteria. The
participants (n=140) were randomly assigned 1:1 into two groups, an intervention
group, and a control group. They determined that both groups had comparable
baseline characteristics. The intervention group received 400mg once daily at bedtime
from 28 weeks’ gestation. The control group received standard care. The pregnant
women were followed up once every two weeks until delivery. The primary outcome
of the study was the rate of premature birth prior to 37 weeks’ gestation. Rehal et al.
(2021) had conducted a study to observe the effects of vaginal progesterone on
reducing preterm rates in twin pregnancies with administration from 13 weeks’
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gestation to 34 weeks’ gestation. They had determined that progesterone
administration had resulted in a reduction in preterm rates before 24 weeks’ gestation,
but did not have a statistically significant effect after 24 weeks. Thus, the lack of
effect that was noted by Shabaan et al. (2018) may be due to the late administration of
progesterone, as their methods commenced the trial from 28 weeks onwards. An
earlier administration of progesterone, as was conducted in the methods by Rehal et al.
(2021), may have resulted in more significant results. Additionally, the sample size in
the study conducted by Rehal et al. (2021) was much larger than that of Shabaan et al.
(2018) (n=1194 vs. n=140). This larger sample size would have allowed for
statistically significant results to be discovered, whereas associations may have been
missed in the analysis conducted by Shabaan et al. (2018). Furthermore, a larger
progesterone dose was used in the methods employed by Rehal et al. (2020) compared
to Shabaan et al. (2018) (300 mg twice daily compared to 400 mg once daily). This
larger dose of progesterone may have had a greater therapeutic effect and thus had a
greater effect on preterm labor rates and postnatal outcomes. This would explain the
positive effect that Rehal et al. (2021) observed in neonatal mortality and morbidity
rates in women that received progesterone, compared to no effect in the study
conducted by Shabaan et al. (2018). Rehal et al. (2021) also noted that progesterone
administration reduced preterm birth rates in women before 24 weeks’ gestation
compared to no effect in the study conducted by Shabaan et al. (2018). A strength of
the study conducted by Shabaan et al. (2018) was their analysis of the characteristics
of each group to ensure that bias due to demographical differences was not missed.
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2.9 Review of Empirical Literature to Identify Limitations and Possible Risk of Bias
The study conducted by Merced et al. (2019) contained a sample size of 132
participants which is small and could raise questions about the validity of the results.
Also, the sample size allowed for a power of 80% which is on the lower end of the
acceptable spectrum and gives rise to the potential for a type II error. Hence, there is a
possibility that the study conducted by Merced et al. (2019) may have had false
clinical implications. Furthermore, Merced et al. (2019) did not calculate a p-value for
their results to demonstrate the statistical significance of their data. As opposed to
Merced et al. (2019), Rehal et al. (2021) included a placebo in their control group that
allowed for double-blinding in their study. Thus, they had a reduction in their level of
potential bias compared to Merced et al. (2019). Rehal et al. (2021) did calculate a pvalue for their results, but was not statistically significant for their primary outcome
(p=0.17). Furthermore, the large sample size utilized by Rehal et al. (2021) further
ensured that the study had a low risk of bias and was generalizable to the population.
Another limitation of Rehal et al. (2021) was that unlike Merced et al. (2019), they did
not consider confounding factors such as cervical length in their analysis of their data.
This may negatively influence the external validity of their results.
Unlike Merced et al. (2019) and Rehal et al. (2020), Shabaan et al. (2018)
included only women that were naturally conceived as part of their inclusion criteria.
Women that undergo artificial reproduction are at an increased risk of miscarriage and
preterm birth. Thus, there is a potential for bias in the studies conducted by Merced et
al. (2019) and Rehal et al. (2020) if there was a greater number of women that
conceived through artificial reproduction in one group compared to the other.
Although randomization is thought to diminish this risk, there is still a chance that
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uneven allocations can occur that may skew results. Thus, it is essential to conduct an
analysis of the characteristics of each group to ensure that demographical factors do
not have an impact on the validity of the results. This analysis was not conducted by
Merced et al. (2019) and Rehal et al. (2020).

2.10 Conclusion
Thus, previous studies have investigated the effects of monotherapy with
cervical pessaries and vaginal progesterone administration on the effects of preterm
birth rates and neonatal mortality and morbidity in twin gestations. The three studies
chose to be reviewed in depth have demonstrated that the administration of cervical
pessary resulted in a reduction in preterm birth rates. However, there was a mixed
result noted in investigations on the effect of using vaginal progesterone on the rates
of preterm births. Rehal et al. (2020) noted that the use of vaginal progesterone
reduced the rates of preterm birth prior to 24 weeks’ gestation, but did not influence
preterm birth rates between 24 to 38 weeks’ gestation in twin gestation. Conversely,
Shabaan et al. (2018) found no association between the use of vaginal progesterone
and preterm birth rates in twin gestation. The difference in these results may be due to
disparities between the methodology employed by these two studies. It was further
noted that the use of cervical pessaries did not have an effect on neonatal mortality but
did reduce the incidence of morbidity. Rehal et al. (2020) observed a reduction in both
neonatal mortality and morbidity with the use of vaginal progesterone during
pregnancy. In contrast, this reduction was not observed by Shabaan et al. (2018) who
found no association between neonatal mortality and morbidity with the use of vaginal
progesterone. Again, this difference may be related to the differing methodology
employed by these two studies.
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To date, there has been no study that has investigated the effect of combined
cervical pessaries and vaginal progesterone administration on preterm delivery rates in
twin gestation. Although cervical pessaries have been found to reduce preterm
delivery rates in this demographic and can be used as a potential prophylactic
intervention, their effect may be amplified with the use of vaginal progesterone.
Furthermore, Merced et al. (2019) investigated the effect of cervical pessary insertion
on preterm rates in twin pregnancies, but had this device inserted after 24 weeks of
gestation. Thus, it is unknown what effect an earlier administration of this device
would have on preterm delivery rates. Hence, this proposed study aims to fill this gap
in the available literature by determining the effects of the early insertion of combined
cervical pessary and vaginal progesterone on preterm delivery rates and neonatal
mortality and morbidity in twin gestation. The insertion of combined progesterone and
cervical pessary has been found to reduce the rates of preterm pregnancies in singleton
gestations by 10 to 20%. It is estimated that the use of these interventions in twin
gestations will have a similar rate of effect.
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CHAPTER 3: STUDY METHODS
3.1 Study Design
This is a prospective multicenter, open-label randomized control clinical trial
to compare combined vaginal progesterone and cervical pessary placement in the late
first trimester (11 to 14 weeks’ gestation) in DCDA twin gestations until 37 weeks
and 6 days’ gestation or birth vs. standard care on the rate of preterm births. The
pregnant participants will be randomly assigned (1:1) to a Control Group (no
intervention, standard management) versus a Treatment Group (vaginal
progesterone and the Arabin cervical pessary placed in late first trimester in twin
gestations). The randomization will be done using a computer-generated system with
balanced blocks consisting of 20 patients in each block. We will also administer a
questionnaire and do an analysis of the participants’ electronic medical records
(EMR) to track their medical histories.

3.2 Study Setting and Population
Patients will be recruited from the twelve sites of Maternal-Fetal Medicine
Unit Centers and sub-sites within the Maternal Fetal Medicine Units (MFMU)
Network. The primary research will be performed at the Yale Maternal Fetal Medicine
Center at the Yale New Haven Hospital (YNHH). It is imperative to have a large study
consortium to ensure an adequate sample size for statistically significant results. It is
estimated that approximately 160,000 deliveries are completed annually within the
MFNU Network.1 Thus, MFMU clinical centers will provide a participant pool to
conduct a large clinical trial that focuses on preterm birth in multiple gestations with
an emphasis on establishing potential interventions.1 Furthermore, it is expected that
the results obtained from participants recruited from the MFMU Network will be
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generalizable given that these patients are not unique in their demographic
characteristics.1
The participant population in this study is pregnant individuals with DCDA
twin gestations that are being treated by the obstetric team in the MFMU Network
Centers and sub-sites. An invitation will be sent to the MFMU centers prior to the
commencement of the study.
Inclusion criteria will include DCDA twin gestation; gestational age between
11 to 14 weeks of gestation at the time of enrolment; participant age 18 years or older;
no know chromosomal abnormality; normal cell-free fetal DNA testing; no known or
suspected fetal structural abnormalities; uncomplicated pregnancy.
Exclusion criteria will include monochorionic diamniotic twin gestation;
triplets or higher-order pregnancies; history of prior preterm delivery; smoking ≥ 10
cigarettes per day; alcohol or illicit drug consumption; singleton gestation; cervical
insufficiency; known uterine malformations; history of hepatic dysfunction or
gestational cholestasis; history of thromboembolic disease; recent (within one year) or
current malignancy; vaginal bleeding; difficulty for follow-up; cervical cerclage
inserted prior to the study; contraindication to treatment with progesterone; women
with progesterone and peanut allergies (given that progesterone supplements may
contain traces of peanut)

3.3 Subject Protection and Confidentiality
To ensure the safety of participants and compliance with ethical requirements,
ethics approval will be obtained from the Intuitional Review Board prior to the
commencement of the study. Given that the study involves vulnerable populations
(pregnant individuals and unborn fetuses), it is essential that ethics approval is cleared
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by the Institutional Review Board. To ensure that all necessary steps are completed
prior to the submission for ethical clearance, the online Research Ethics and Safety
Checklist for Undergraduate Experiments (RESCUE) form will be completed. It was
determined that the CITI Human Subjects Research training module, Clearance for
Human Subjects Ethical Research (CHSER), Participant Information Sheet (PIS),
Informed Consent Form (ICF), and Fieldwork Safety Plan (FSP) must be completed.
Following this, an ethics approval document and risk assessment form should be
conducted. All forms will be sent to the research supervisor for review and clearance
prior to sending to the College Ethics Review Committee (CERC) at Yale. After any
necessary changes to the documents as per the CERC are completed, the documents
can then be submitted to the Institutional Review Board for a final ethics clearance.
To ensure the confidentiality of all participants, the HIPAA guidelines will be
strictly adhered to by all researchers involved in the study. The patient health
information will be limited only to staff that has a direct need to access the
information as part of their role in the study. Furthermore, all staff involved in the
study will undergo proper medical ethics and HIPAA training. Jotforms will be used
as an online HIPAA-compliant tool to allow patients to input their health information
through a secure online form. The electronic transfer of patient information will be
avoided unless deemed necessary. If electronic transfer is required, then patient
information will undergo end-to-end encryption prior to transfer to ensure it remains
secure. After the collection of all data, patient information will be de-identified prior
to analysis to ensure that information remains confidential. Furthermore, trial
coordinators will ensure quality control screening, verification of protocol adherence,
and overseeing data handling.
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3.4 Recruitment
We will use a consecutive sampling method for the recruitment process over a
6-month period. All individuals with DCDA twin pregnancies attending the MFMU
Centers before 14 weeks’ gestation will be considered for inclusion in this trial,
provided that they do not meet any of the aforementioned exclusion criteria. The site
coordinators at the MFMU locations will be asked to provide potential participants
with written information about the study and the trial. Those who agree to participate
will provide the recruitment team with the authority to release their contact
information to the research team. Prior to inclusion in the study, eligible participants
will be screened by midwives or gynecologists to ensure they are healthy and able to
participate in the study. All pregnancies will be dated by crown-rump length during
the first trimester, and chorionicity will be determined. Eligible participants who agree
to participate in the study will then be provided with a fully detailed participant
information sheet and with the investigators contact information for any queries or
questions before agreeing to participation. They will then be provided with a written
informed consent form to sign. An incentive of a $100 gift card will be given to each
participant that completes the trial. After signing the informed consent, participants
will have the option to drop out of the study for any reason and at any time.
Furthermore, providers as part of the investigative team will have the option to
withdraw the participants from the study if urgent medical reasons arise. Based on the
intention to treat principle, all subjects will be included in the analysis.
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3.5 Key Study Variables, Measures, and Operationalization
3.5.1 Study Intervention
At the time of recruitment, we will obtain a detailed medical history for all
participants, including their medical, personal, obstetric, and menstrual history
through both EMR and questionnaires. The gestational age will be estimated if there is
a reliable date available. If this is not available, then the providers will obtain the
gestational age using a first-trimester ultrasound crown-rump length. All participants
will receive their usual antenatal care for multiple gestations, including iron and
calcium supplements. The eligible participants (pregnant individuals) will be
randomly allocated in a 1:1 to two groups: Group 1 (Cervical Pessary and
Progesterone Group) will have the insertion of an Arabin cervical pessary between 11and 14-weeks’ gestation, followed by administration of 400 mg of vaginal natural
progesterone once daily. These interventions will continue until 37 weeks’ gestation.
Group II (control group) will receive no additional treatment beyond standard care.
The independent variable in this study will be the combination therapy of the cervical
pessary and vaginal progesterone. The dependent variable will be the mean gestational
age at delivery and neonatal morbidity and mortality. Control variables include
standard antenatal care for multiple gestations. The primary outcome of interest is the
difference in the rate of preterm birth between the intervention group and the control
group. The secondary outcomes include overall gestational age at delivery; preterm
birth before 35, 34, 32 and 28 weeks of gestation; cervical length changes throughout
pregnancy (measured in millimeters via transvaginal ultrasound); birth weight;
APGAR score at birth and five minutes after; admission to the NICU and the time
spent there if needed (of one or both of the twins); and composite neonatal outcomes
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of morbidity and mortality (the occurrence of any of the following events: RDS, IVH,
sepsis, NEC and death before hospital discharge).

3.5.2 Follow-up
Participants in both the treatment and control groups will be followed up
during their antenatal visits at the multicenters every week until they deliver. During
each visit, they will be asked to report symptoms of preterm labor such as abdominal
colic, heaviness, cramps, and sudden expulsion of a gush of fluid. They will also be
asked about compliance and any notable side effects from use of the daily vaginal
progesterone. During these weekly visits, the participants will also undergo an
ultrasonography scan to evaluate the wellbeing of the fetuses. Any complications,
such as intrauterine growth restriction, placental abruption, preeclampsia, etc. will be
noted during these visits. At the time of delivery, neonatal birth weight, delivery data,
referral to neonatal care unit, and any intrapartum or postpartum events will be
recorded. The women and neonates will continue to be followed up on a monthly basis
for 12 months after delivery to monitor for neonatal morbidity and mortality rates.

3.6 Methodology Considerations
There are a number of confounding variables in this study, such as cervix
shape; prior cervical operations, such as cone biopsy, LEEP, etc.; compliance to
vaginal progesterone; fetal abnormalities; miscarriage; bacterial vaginosis during
pregnancy; GBS carrier mother; premature rupture of amniotic membranes; GDM;
preeclampsia; and thromboembolic event. Certain characteristics pertaining to
maternal factors such as age, ethnicity/race, educational level, socioeconomic status,
BMI, or mental health status may also have confounding effects. These confounding
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variables will need to be taken into consideration when completing the data analysis.
Furthermore, the participants’ mental health status may predispose her to cervical
disease that will be accounted for when analyzing the data. For this reason, multiple
logistic regression analyses will be conducted in the data analyses period to control for
any or all the listed confounding variables.

3.7 Blinding of Interventions/Outcomes
Due to the nature of this study, the participants and the medical providers
inserting the cervical pessary will not be able to be blinded to their group allocations.
Given that this an open-label clinical trial YNHH Investigational Pharmacy will be
informed to distribute regular packets of progesterone to the intervention and standard
of care group as applicable. All participants, pharmacists, investigators, and other
research personnel will be informed of the nature of the study design, and they will
not be blinded to the intervention during treatment, data collection, and data analysis.
The data analysis will be performed once the data has been charted, cleaned and
readied.

3.8 Assignment of Intervention
The randomization will be performed through a computer-generated random
assignment system with balanced blocks to ensure equal allocation to each group.
After the allocation to groups, the control group will be asked to attend weekly followup appointments at the Yale Maternal Fetal Medical Center to receive their standard
care and monitoring of maternal and fetal health. The intervention group will be
booked into an urgent appointment to have the insertion of a cervical pessary prior to
14 weeks of gestation. At this appointment, they will receive 7 doses of vaginal
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progesterone capsules to administer every night for the next week until their next
follow-up. The subjects will receive instructions and education on how to selfadminister the vaginal capsule. The subjects will receive a week supply of daily
vaginal progesterone capsules at each weekly follow-up appointment.

3.9 Adherence
Because one intervention modality (i.e., progesterone) is self-administered
based on the subject’s intake location, the adherence protocol will be assessed by
having the participant complete a log of medication taken and any missed doses and to
return the empty packet of the previous supply. We will consider the compliance to be
adequate for inclusion in the data analysis if the participant completed 80% or more of
the prescribed doses, which is in line with the standard cut-off for compliance in any
clinical trials. Furthermore, the cervical pessary will be monitored by the primary
clinician to note any deviations subjective to the patient. We will provide
appointments at various time to fit the participants’ schedule and transportation for
those who need it. If a participant is unable to make an appointment, their next week’s
vaginal progesterone packet can be ordered to their local pharmacy to pick up.

3.10 Monitoring for Adverse Events
While adverse events may occur in this clinical study, they are expected to be
extremely rare. The primary investigator of the study will be obliged to notify the
subjects and the medical research ethics committee if any unforeseen negative
outcomes, adverse effects, or disadvantages secondary to participation in the study are
observed that are greater than initially noted in the research proposal. In this case, the
study would be suspended until it has been reviewed by the medical research ethics
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committee. An adverse event is defined as an undesirable experience that occurred to a
participant in the study, regardless of whether this is related to the interventions.
Adverse events that may occur due to progesterone administration include fluid
retention/bloating, breast pain, drowsiness, depression, hot flushes, dizziness, vaginal
discharge, abdominal pain or cramping, and more.2 Due to the vaginal administration
method of progesterone, there are limited levels of progesterone that reach systemic
circulation in this study, compared to other routes of administration. The main adverse
event associated with cervical pessaries is an increase in vaginal discharge.3 All
participants will be informed of the potential adverse effects prior to acquiring written
consent. Furthermore, all participants will be asked to report experience any adverse
events at each weekly follow-up visit. These adverse events will be monitored until
the situation becomes stable or the adverse event has abated. Additional tests, medical
procedures, or referrals to medical specialists/general physicians will be performed as
indicated.
A serious adverse event is defined as a medical occurrence or event that results
in a life-threatening condition, death, permanent or significant disability,
hospitalization, a birth defect or congenital abnormality, or is a new event in the trial
that is likely to affect the safety of participants. In the case of a serious adverse event,
the study will be suspended until a further review is conducted and the ethics
committee that granted approval will be informed.

3.11 Data Collection
Data will be collected at randomization and at each weekly follow-up
appointment at the Yale Maternal Fetal Medicine Center and other MFMU Network
centers using a standard questionnaire that will be provided to each medical provider
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involved. All centers will list basic demographic and clinical characteristics data
obtained from the EMR and questionnaires. This provide information on the maternal
racial group/ethnicity, age, educational level, socioeconomic status, mental health,
BMI, or any substance use history. These questionnaires are expected to limit potential
confounders, and the research team will have a better estimate in the management of
confounders as the study progresses. This will be recorded using the Epi Info software
(Centers for Disease Control and Prevention) and documented in the subject’s study
profile. The questionnaire will include questions about any adverse events experienced
by the participant, results of ultrasonography, any symptoms of preterm labor, etc. If
the participant is unable to attend the clinic for any follow-up appointment, data will
be collected through a telephone interview where they will be asked to answer the
questionnaire. We will also document cervical length changes throughout pregnancy
(measured in millimeters via transvaginal ultrasound) and determine if the mother has
cervical insufficiency.
After the participant arrives for delivery we will review their medical record to
acquire data on the labor, delivery, and any complications that may have arisen for the
participant or neonates. The gestational age at delivery and whether or not it is preterm
(< 37 weeks) will be recorded (primary outcome data), with the division of groups in
preterm birth before 35, 34, 32, and 28 weeks of gestation (secondary outcome data).
We will assess the birth weight of the baby as part of the standard operating protocols,
hence no, hence no additional personnel will be required. The nursing team will ensure
that the APGAR score at birth and five minutes after is charted correctly. Admission
to the NICU and the time spent there if needed (of one or both twins) will be noted
with yes and no options (dichotomous data). A set of lists for composite neonatal
outcomes of morbidity and mortality including 1. RDS, 2. IVH, 3. Sepsis, 4. NEC and
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5. Death before hospital discharge will all be enlisted as dichotomous variables by the
research assistants which will be regularly cross-checked and finally verified by the
research heads at the different centers
The participants will then attend a monthly follow-up appointment for 12
months after delivery. At the first follow-up appointment after delivery, they will be
asked about their delivery and labor details and whether any complications were
experienced to ensure that information is not missed. Additionally, they will be asked
screening questions for the neonates’ health status, including regular development
questions, any symptoms of infections that may have been noted, and any concerns the
mother has. The neonates’ weight, length, and head circumference will also be
measured at each follow-up to monitor growth.

3.12 Sample Size
Sample size will be calculated based on a 20% reduction of the reported 60%
preterm birth rate in twin pregnancies before 37 weeks’ gestation.4 The calculation
was done based on Cox Proportional Hazard Regression with an α error of 0.05 and a
β error of 20% (i.e. with a power of 80%). Accordingly, the sample size was
calculated to be 97 participants in each arm, but when accounting for a maximum loss
to follow-up of 25% that equates to 122 participants in each arm. The effect size
chosen was 0.1 in order to get a larger sample size because the relationship between
the primary outcome of gestational age and the independent variable of cervical
pessary and progesterone is more likely to be detected with a larger sample size.
Sample size calculation was done using G*Power, version 3.1.9.6 for macOS.5
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3.13 Analysis
Statistical analysis will be carried out on an intention-to-treat basis, thus all
participant will be included in the results. No interim analyses will be performed. In
cases of a strong positive effect of the combination intervention, the trial will proceed.
Negative effects will be detected by a data safety monitoring committee. Outcomes
will be evaluated using Cox Proportional Hazard Regression model, as well as with
secondary outcomes looking at gestational age at birth < 35, < 34, < 32, and < 28
weeks’ gestation. Student t-test will be used for continuous outcomes of secondary
variables (birthweight, cervical length changes, etc.), and Chi-Square analysis will be
used for categorical data of secondary outcomes.

3.14 Timeline and Resources
The study timeline includes 6 months for recruitment and baseline data
collection, 12 months to assess outcomes, and 6 months for data analysis. It is
estimated that the research team at the Yale Maternal Fetal Medicine Center at YNHH
will include one principle investigator, one project coordinator, one project manager,
medical providers as needed that will provide antenatal care to the participants,
administer interventions, and collect and upload weekly follow-up data, one data
analyst, 3-4 research assistants, five data compilers, and five data analysts. Medical
offices as needed per site and one procedure room will be required at the Yale
Maternal Fetal Medicine Center to conduct follow-up appointments and insert cervical
pessaries. Cervical pessaries and vaginal progesterone capsules will need to be
ordered. Given that all 12 MFMU Networks sites may partake in the study, there will
be up to an additional 11 site coordinators, and medical providers as needed per site.
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The intake surveys coordinators, and data collection and entering will be led by the
resident physicians or medical fellows. Providers will be compensated for their time.
Additionally, equipment for the insertion of cervical pessaries, such as
speculum, will be required. Subscriptions for the online data tools that will be used in
this investigation will need to be organized. This includes Jotforms and the SPSS
software package. Overall, it is expected that this study will span across a two-year
period. It is expected to start in January 2022 and be completed by January 2024.

3.15 Accounting for Loss to Follow-Up
The primary strategy that will be utilized to avoid bias due to loss to follow-up
and consequent missing data will be initial prevention. This will be achieved by
careful design of the study, high level of training of staff, developing mechanisms to
ensure that participants can be easily contacted, and implementing data quality
procedures. Each arm of the study will include 122 participants, rather than the
calculated 97 participants, to account for a maximum loss to follow-up of 25%. The
secondary strategy to avoid loss to follow-up bias is to use an intention-to-treat
methodology in analysis. Thus, even if participants drop out or are lost to follow-up,
they will be included in the analysis of the data. Additionally, the rate of loss to
follow-up and level of missing data will be reported in the final paper to ensure
transparency.
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CHAPTER 4: CONCLUSION
4.1 Advantages and Disadvantages
There are several advantages and disadvantages of the proposed study and its
methodology that may impact the reliability of the data to be obtained. The most
central strength of this study is the notion that we will contribute to existing literature
since no study has been done that looks at early use of vaginal progesterone, in
combination with cervical pessary. Other strengths of the study include the
randomized, controlled design, which is expected to minimize bias, including bias
from confounding factors. Furthermore, the randomized nature of the study is
expected to enhance the generalizability of the study and combat any confounding
variables. Additionally, there will only be a limited number of staff that will be
involved in the insertion of the cervical pessary, which should have a positive impact
on the validity of the study.
The large sample size is expected to have a positive impact on the power and
statistical significance of the results. However, this is also seen as a limitation since it
is unknown whether obtaining such a large number of participants in a 6-month time
period given the narrow inclusion criteria is feasible. The ultimate sample size may be
significantly smaller than desired if a substantial number of viable participants are not
found. Thus, the study may have to span for a longer period of time than intended to
ensure adequate power and statistical significance. This will be addressed by
informing the participant that they will receive optimal care and surveillance
throughout their pregnancy, which will benefit themselves and the twins. We will also
incentivize the participants with the $100 gift card upon completing the trial.
A limitation of the study is that the open nature of the study with no blinding
or masking may result in the introduction of bias. This unfortunately cannot be
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avoided due to the nature of the interventions. However, given that the primary
endpoint of the study is an objective variable (gestational age at delivery), it is
believed that the non-masked nature of the trial should not result in a significant level
of bias. A factor that may compromise the external validity of the study is that the
majority of women with twin pregnancies will have conceived from assisted
reproductive technology. This consequently may have a negative impact on the
generalizability of the results.
A potential limitation is the lack of previous studies that have investigated the
effects of early implementation of progesterone and cervical pessaries on the rates of
preterm births in multiple gestations. As a result, the data cannot be compared to
empirical evidence. However, futures studies would be able to reproduce this study
and see if they yield different results. Also, a percentage change reduction in preterm
births that will be expected to arise from the interventions proposed in this study was
not based on previous studies and findings. Similar studies that were conducted in
singleton pregnancies have demonstrated an approximately 20% reduction in the rate
of preterm births. Thus, it is expected that the results of this study will mimic these
results and consequently lead to a 20% reduction in the rate of preterm births in twin
gestations with the use of progesterone supplementation and cervical pessary insertion.

4.2 Clinical and/or Public Health Significance
The use of either vaginal progesterone or cervical pessary is known to
successfully delay preterm birth in singleton pregnancies, but no studies have provided
statistically significant data about an intervention that prevents or delays premature
birth in twin pregnancies.1,2 Therefore, there is no established standard of care or
reliable treatment to increase the average gestational age and lower the rates of
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preterm birth in twin pregnancies.3 With the trend of increasing incidence of twin
pregnancies, there are higher rates of preterm birth and higher rates of morbidity and
mortality associated with preterm birth in this population compared to singleton
pregnancies.4 Premature birth is responsible for greater than 50% of all neonatal
deaths for multiple gestations; an effective treatment is needed now more than ever.5 If
this intervention proves to be effective it can lead to a new standard of care and
significantly decrease the morbidity and mortality that affect the majority of twin
pregnancies.
Because most studies look for a 50% decrease in preterm birth between the
intervention and control group, a goal of a 20% decrease will give this study a better
chance at success.6-10 The study is unique since it will include a multitude of important
factors that can help determine if the intervention truly is more effective than those used
in previous studies, even if the rate of preterm birth is not significantly reduced. Some of
these important secondary outcomes are overall gestational age; level of preterm birth
based on if the twins are < 35, < 34, < 32, and < 28 weeks’ gestation at birth; birth
weight; cervical length during pregnancy; APGAR score; admission to the NICU and the
time spent there if needed; and composite neonatal outcomes (the occurrence of any of
the following events: RDS, IVH, sepsis, NEC and death before hospital discharge).10,11
Discovering statistically significant improvements in these outcomes could also establish
this intervention as the treatment of choice for preventing morbidity and mortality in twin
gestations that are premature.
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Appendix A: IRB Consent Form
Instructions and invitation to participate:
You are invited to participate in our study that aims to investigate the effect of early
administration of vaginal progesterone and cervical pessaries on the rates of preterm
births in twin gestations. Currently, twin gestations account for approximately 60% of
all preterm births. This places these babies at a great risk of potential harm to their
health. We aim to reduce this risk by devising an intervention that will reduce the
rates of twin babies that are born preterm. In this study, you will be randomly
allocated to a group that either receives combined vaginal progesterone and cervical
pessary, or to a group that receives no additional interventions. We will then analyze
your pregnancy outcomes and the outcomes of your babies and compare the rates of
preterm births and the babies’ health status. In order to decide whether you want to
participate in this study, we will provide you with an additional form with all of the
risks and benefits of participation. Additionally, we invite you to have a consultation
with our primary investigating team so that you are openly able to ask any questions
or raise concerns. By providing you with this detailed information, we want to make
sure that you make an informed decision regarding your participation.
Economic Considerations
There will be no monetary benefits to participating in this study.
Audio/Video Recording
All consultations will be recorded to assist with analysis of our data. These will be
kept confidential and will only be used by the analysts in the study. No distribution of
these videos will occur and they will be destroyed on the completion of the study.
Please sign below if you are willing to have this interview recorded (specify audio or
video). You may still participate in this study if you are not willing to have the
interview recorded.
 I do not want to have this interview recorded
 I am willing to have this interview recorded
Signed: _____________________________________
Date: __________________
Disclaimer:
• A video recording in which the your name, likeness, image, and/or voice will
be included will be recorded
• By signing this form, you give us the right to make, use and publish
Recordings in whole or in part in media forms now known (such as film,
slides, and digital audio) or developed in the future. This includes the right to
edit or duplicate any images/recordings
• There will be NO reproduction, distribution, performance, or display of
images/recordings
• By signing this form, you relinquish the rights to inspect or approve the
finished product or printed/published matter that uses the images/recordings
or versions of the images/recordings;
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If you are injured by this research
In the event that any research-related activities result in an injury, treatment will be
made available including first aid, emergency treatment, and follow-up care as
needed. Cost for such care will be billed in the ordinary manner to you or your
insurance company. No reimbursement, compensation, or free medical care is offered.
If you think that you have suffered a research-related injury, contact [PI name] right
away at [insert phone number].
Privacy/Confidentiality
The information regarding your involvement with the study will be recorded in your
Electronic Medical Record. From there, this information will be accessible by your
providers who participate in managing your health. Your medical records will be
accessible by the investigators of this study. Additionally, it is possible that the Food
and Drug Administration (FDA) may need to review all records of participants in the
study, however these personnel are bound by the rules of confidentiality to not
disclose your name or information to others. Additionally, the Yale Human Research
Protection Program Committee may access study records to conduct an internal audit.
In this case, all members of the committee are required to keep all information and
records confidential. All your identifiable information will remain confidential for the
entire duration of the study. Furthermore, your data will be de-identified prior to
analysis to ensure confidentiality. Regardless, all study personnel are legally bound by
the rules of confidentiality and breaches of these rules will have severe legal
repercussions.
Data Sharing
De-identified data from this study may be shared with the research community at
large to advance science and health. We will remove or code any personal information
that could identify you before files are shared with other researchers to ensure that, by
current scientific standards and known methods, no one will be able to identify you
from the information we share. Despite these measures, we cannot guarantee
anonymity of your personal data.
Clinical Trial
This study is classified as a clinical trial and will be registered online at
http://www.ClinicalTrials.gov. The website will not include any information that can
identify you, but will include a summary of results once the research is completed.
You can search this publicly-available website at any time.
Taking part is voluntary
Your involvement is voluntary, and you may refuse to participate before the study
begins, discontinue at any time, or skip any questions/procedures that may make you
feel uncomfortable, with no penalty. It will not harm your relationship with the
investigators in this study or with your doctors/medical professionals. If you
withdraw, there will be no ongoing collection of data. However, data that was
previously collected may still be used in the analysis of the results to ensure that the
integrity of the study is maintained.
Withdrawal by investigator, physician, or sponsor
The investigators, physicians or sponsors may stop the study or take you out of the
study at any time should they judge that it is in your best interest to do so, if you
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experience a study-related injury, if you need additional or different
medication/treatment, or if you do not comply with the study plan. They may remove
you from the study for various other administrative and medical reasons. They can do
this without your consent.
If you have questions
The main researcher conducting this study is [principal investigator’s name], a
[professor, graduate/undergraduate student, etc.] at Yale University. Please ask any
questions you have now. If you have questions later, you may contact [principal
investigator’s name] at [email address] or at [phone number]. If you have any
questions or concerns regarding your rights as a subject in this study, you may contact
the Institutional Review Board (IRB) for Human Participants at 607-255-5138 or
access their website at http://www.irb.cornell.edu. You may also report your concerns
or complaints anonymously through Ethicspoint online at www.hotline.cornell.edu or
by calling toll free at 1-866-293-3077. Ethicspoint is an independent organization that
serves as a liaison between the University and the person bringing the complaint so
that anonymity can be ensured.
You will be given a copy of this form to keep for your records.
Statement of Consent
I have read the above information, and have received answers to any questions I
asked. I consent to take part in the study.
Your Signature
Date
Your Name (printed)
Signature of person obtaining consent
Date
Printed name of person obtaining consent
This consent form will be kept by the researcher for at least five years beyond the end
of the study.

Reference:
1. IRB Consent Form Templates | Cornell Research Services.
Researchservices.cornell.edu. https://researchservices.cornell.edu/forms/irb-consentform-templates. Published 2021. Accessed July 2021.
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Appendix B: Trial Profile

Assessed for eligibility (between 11 to 14 weeks’
gestation and twin gestations) (n)

Excluded (n)
Did not consent
Did not meet
inclusion criteria
- Met exclusion
criteria

Randomized 1:1 into two groups

Control Group (no intervention) (n)

Open label
received
standard
cares. No
additional
interventions

Analyzed in the Control Group (n)
(including lost to follow-up and
withdrawals of participation)

Combined Vaginal Progesterone
and Cervical Pessary Group (n)

Open label,
insertion of
cervical pessary
between 11- and
14-weeks’
gestation and
400mg of vaginal
progesterone daily
until delivery or
37 weeks’
gestation

Analyzed in Combined Vaginal
Progesterone and Cervical Pessary
Group (n) (including lost to follow-up
and withdrawals of participation)
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Appendix C: Maternal Demographic and Medical History Data Collection
Table 3: Maternal Demographic and Medical History Data
Maternal Physical
Control Group (n=122)
Characteristics and
Demographics

Combined Vaginal
Progesterone and Cervical
Pessary Group (n=122)

Maternal age at time of
enrolment
Maternal gestational age at
time of enrolment
Education Level
Ethnicity
Body-Mass Index during
pregnancy
Gravidity and Parity
Marital Status
Household Monthly Income
Behaviors During
Pregnancy

Control Group (n=122)

Combined Vaginal
Progesterone and Cervical
Pessary Group (n=122)

Control Group (n=122)

Combined Vaginal
Progesterone and Cervical
Pessary Group (n=122)

Alcohol Consumption
Actively Smoking
Passively Smoking
Highly Active Level
Folic Acid Supplementation
Illicit Drug Use
Screening
Pregnancy Outcomes

Pregnancy-induced
hypertension
Gestational diabetes mellitus
Anxiety
Depression
GBS colonization
Eclampsia/pre-eclampsia
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Mullerian anomaly
Bacterial vaginosis
HELLP Syndrome
Abortion
Spontaneous Abortion
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Appendix D: Pregnancy Outcomes (Detailed)
Table 4: Pregnancy Outcomes for Mother and Neonates
95%
Relative
Control Combined
Confidence
Risk
Group
Vaginal
Interval
(n=122) Progesterone
and Cervical
Pessary Group
(n=122)

P-value

Delivery Outcomes
Total Deliveries
<28 weeks
28 – 30 weeks
30 to 32 weeks
32 to 34 weeks
34 to 36 weeks
>37 weeks
Preterm < 37 weeks
Full-term
Spontaneous
Deliveries
<28 weeks
28 – 30 weeks
30 to 32 weeks
32 to 34 weeks
34 to 36 weeks
>37 weeks
Preterm < 37 weeks
Full-term
Induction Required
Post-term
PROM
Placental abruption
Hypertension
Gestational
Diabetes
Oligohydramnios
or IUGR
Fetal Distress
Delivery Mode
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Natural Vaginal
Birth
Operative Vaginal
Birth
Caesarean section
prior to labor
Caesarean section
after onset of labor
Neonatal Outcomes
Live births
Death prior to
discharge from
hospital
Admission to
NICU
APGAR Score at 1
minute
APGAR Score at 5
minutes
Respiratory distress
syndrome
Intravascular
hemorrhage
Sepsis
Necrotizing
enterocolitis
BW <1,500g
BW <2,500g
BW ≥ 2,500g
Adherence to
Treatment
≥80% of vaginal
progesterone
≥50% of vaginal
progesterone
Adverse Effects of
Interventions
Vaginal Discharge
Pain
Itching
Bleeding
Other

63

Appendix E: Sample Size Calculations
Completed using G*Power, version 3.1.9.6. for MacOS
- Based on 20% reduction of reported 60% preterm birth rate in twin
gestations prior to 37 weeks
- Using Cox Proportional Hazard Regression
- α error = 0.05
- β error = 20%
- Power = 80%
- Calculated to be 97 in each arm

-

Accounting for maximum loss to follow-up = 25%
Required sample size = 1.25*97 = 122
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